| Symbol | RGNX |
|---|---|
| Name | REGENXBIO INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 9804 MEDICAL CENTER DRIVE,SUITE 210, ROCKVILLE, Maryland, 20850, United States |
| Telephone | +1 240 552-8181 |
| Fax | — |
| — | |
| Website | https://www.regenxbio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001590877 |
| Description | Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). Additional info from NASDAQ: |
2026-08-27 23:03
Ciongoli Gregory Austin 🟢 acquired 187.6K shares (1 derivative) of REGENXBIO Inc. (RGNX) at $9.36 ($1.6M) Transaction Date: Aug 25, 2026 | Filing ID: 000008
Read more
2026-08-27 20:02
New Form 3 - REGENXBIO Inc. <b>Filed:</b> 2026-08-27 <b>AccNo:</b> 0002023732-26-000007 <b>Size:</b> 6 KB
Read more
2026-08-25 20:57
(70% Positive) REGENXBIO INC. (RGNX) Provides Update on experience for biotechnology investing
Read more
2026-08-25 16:53
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of REGENXBIO Inc. (RGNX)
Read more
2026-08-25 11:05
REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli
Read more
2026-08-06 11:05
REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights
Read more
2026-08-03 11:05
REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights
Read more
2026-07-20 11:34
(99% Neutral) REGENXBIO INC. (RGNX) Announces Clinical Development Update
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07652606 | Expanded Access to RGX-202 | — | — | Temporarily_Not_Available | — | — | ClinicalTrials.gov |
| NCT07236606 | RGX-121-3102 Gene Therapy in Participants With MPS II (Hunter Syndrome) | Phase3 | MPS II | Active_Not_Recruiting | 2025-11-25 | 2031-05-30 | ClinicalTrials.gov |
| NCT06942520 | Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edem… | Phase2 | Diabetic Macular Edema | Recruiting | 2025-03-18 | 2027-12-01 | ClinicalTrials.gov |
| NCT06491927 | Long Term Follow-up for RGX-202 | — | Duchenne Muscular Dystrophy | Enrolling_By_Invitation | 2024-05-08 | 2029-12-01 | ClinicalTrials.gov |
| NCT06103487 | Long Term Follow-Up for RGX-111 | — | Mucopolysaccharidosis I | Enrolling_By_Invitation | 2023-07-24 | 2027-09-01 | ClinicalTrials.gov |
| NCT05693142 | AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular … | Phase2 | Duchenne Muscular Dystrophy | Active_Not_Recruiting | 2023-01-04 | 2028-06-01 | ClinicalTrials.gov |
| NCT05683379 | AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Males With DMD | — | Duchenne Muscular Dystrophy | Active_Not_Recruiting | 2022-12-20 | 2026-09-01 | ClinicalTrials.gov |
| NCT04591834 | Mucopolysaccharidosis Type II Observational | — | Mucopolysaccharidosis II | Withdrawn | 2022-03-01 | 2025-07-01 | ClinicalTrials.gov |
| NCT04480476 | A Retrospective, Natural History Study in Children With CLN2 | — | Late-infantile Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) | Withdrawn | 2021-03-31 | 2022-04-01 | ClinicalTrials.gov |
| NCT04462692 | An Observational Study in Children With CLN2 Batten Disease | — | Neuronal Ceroid Lipofuscinosis Type 2 (CLN2) | Withdrawn | 2021-03-31 | 2023-10-01 | ClinicalTrials.gov |
| NCT04597385 | Long-term Follow-Up for RGX-121 | — | Mucopolysaccharidosis II | Active_Not_Recruiting | 2021-03-14 | 2028-10-01 | ClinicalTrials.gov |
| NCT04571970 | RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Sy… | Phase1 | Mucopolysaccharidosis Type II (MPS II) | Completed | 2021-03-11 | 2024-05-23 | ClinicalTrials.gov |
| NCT04704921 | Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administer… | Phase2 | AMD | Active_Not_Recruiting | 2020-12-29 | 2027-11-01 | ClinicalTrials.gov |
| NCT04514653 | RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants … | Phase2 | Neovascular Age-Related Macular Degeneration (nAMD) | Active_Not_Recruiting | 2020-08-25 | 2027-02-01 | ClinicalTrials.gov |
| NCT04148001 | Identifying and Genotyping Homozygous Familial Hypercholesterolemia (HoFH) Pati… | — | Homozygous Familial Hypercholesterolemia (HoFH) | Completed | 2019-12-04 | 2020-04-08 | ClinicalTrials.gov |
| NCT04080050 | A Long-term Follow-up Study to Evaluate the Safety and Efficacy of RGX-501 | — | Homozygous Familial Hypercholesterolemia (HoFH) | Unknown | 2019-09-30 | 2025-09-29 | ClinicalTrials.gov |
| NCT03580083 | RGX-111 Gene Therapy in Patients With MPS I | Phase1 | Mucopolysaccharidosis Type I (MPS I) | Suspended | 2019-04-03 | 2029-03-06 | ClinicalTrials.gov |
| NCT03566043 | CAMPSIITE™ RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome) | Phase2 | Mucopolysaccharidosis Type II (MPS II) | Active_Not_Recruiting | 2018-09-27 | 2025-08-01 | ClinicalTrials.gov |
| NCT03529786 | Mucopolysaccharidosis Type II Natural History | — | Mucopolysaccharidosis II | Completed | 2017-09-27 | 2022-03-22 | ClinicalTrials.gov |
| NCT03066258 | Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for N… | Phase1 | Neovascular Age-related Macular Degeneration | Completed | 2017-03-29 | 2021-06-17 | ClinicalTrials.gov |
| NCT02651675 | A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH) | Phase1 | Homozygous Familial Hypercholesterolemia (HoFH) | Terminated | 2016-03-01 | 2020-11-27 | ClinicalTrials.gov |
Total clinical trials: 21
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Long-term Follow-Up | Other | Preclinical | Mucopolysaccharidosis II | ACTIVE_NOT_RECRUITING | NCT04597385 |
| RGX-202 | Other | Phase PHASE2 | Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05693142 |
| AAV8 DetectCDx | Other | Preclinical | Duchenne Muscular Dystrophy | ACTIVE_NOT_RECRUITING | NCT05683379 |
| RGX-202 | Other | Phase PHASE2 | Duchenne Muscular Dystrophy | RECRUITING | NCT05693142 |
| AAV8 DetectCDx | Other | Preclinical | Duchenne Muscular Dystrophy | RECRUITING | NCT05683379 |
| RGX-202 | Other | Preclinical | — | TEMPORARILY_NOT_AVAILABLE | NCT07652606 |
| RGX-121-3102 | Other | Phase PHASE3 | MPS II | ACTIVE_NOT_RECRUITING | NCT07236606 |
| Long-term Follow-Up | Other | Preclinical | Mucopolysaccharidosis II | UNKNOWN | NCT04597385 |
| Observational | Other | Preclinical | Mucopolysaccharidosis II | WITHDRAWN | NCT04591834 |
| Single intravenous (IV) dose of human Low Density Lipoprotein Receptor (LDLR) Gene Therapy | Drug | Preclinical | Homozygous Familial Hypercholesterolemia (HoFH) | UNKNOWN | NCT04080050 |
| RGX-314 | Other | Phase PHASE1 | Neovascular Age-related Macular Degeneration | COMPLETED | NCT03066258 |
| AAV directed hLDLR gene therapy | Drug | Phase PHASE1 | Homozygous Familial Hypercholesterolemia (HoFH) | TERMINATED | NCT02651675 |
| RGX-121 | Other | Phase PHASE1 | Mucopolysaccharidosis Type II (MPS II) | COMPLETED | NCT04571970 |
| RGX-121 | Other | Phase PHASE2 | Mucopolysaccharidosis Type II (MPS II) | ACTIVE_NOT_RECRUITING | NCT03566043 |
| Aflibercept (2.0 mg) | Other | Phase PHASE2 | Diabetic Macular Edema | RECRUITING | NCT06942520 |
| RGX-314 Dose 2 | Other | Phase PHASE2 | Diabetic Macular Edema | RECRUITING | NCT06942520 |
| RGX-314 Dose 1 | Other | Phase PHASE2 | Diabetic Macular Edema | RECRUITING | NCT06942520 |
| Aflibercept | Other | Phase PHASE2 | Diabetic Retinopathy (DR) | ACTIVE_NOT_RECRUITING | NCT04567550 |
| ABBV-RGX-314 Dose 4 | Other | Phase PHASE2 | Diabetic Retinopathy (DR) | ACTIVE_NOT_RECRUITING | NCT04567550 |
| Topical Steroid | Other | Phase PHASE2 | Diabetic Retinopathy (DR) | ACTIVE_NOT_RECRUITING | NCT04567550 |
| ABBV-RGX-314 Dose 3 | Other | Phase PHASE2 | Diabetic Retinopathy (DR) | ACTIVE_NOT_RECRUITING | NCT04567550 |
| ABBV-RGX-314 Dose 2 | Other | Phase PHASE2 | Diabetic Retinopathy (DR) | ACTIVE_NOT_RECRUITING | NCT04567550 |
| ABBV-RGX-314 Dose 1 | Other | Phase PHASE2 | Diabetic Retinopathy (DR) | ACTIVE_NOT_RECRUITING | NCT04567550 |
| AAV8 DetectCDx | Other | Preclinical | Duchenne Muscular Dystrophy | RECRUITING | NCT05683379 |
| RGX-202 | Other | Phase PHASE2 | Duchenne Muscular Dystrophy | RECRUITING | NCT05693142 |
| RGX-121-3102 | Other | Phase PHASE3 | MPS II | SUSPENDED | NCT07236606 |
| ABBV-RGX-314 Dose 4 | Other | Phase PHASE2 | Neovascular Age-Related Macular Degeneration (nAMD) | ACTIVE_NOT_RECRUITING | NCT04514653 |
| Topical Steroid | Other | Phase PHASE2 | Neovascular Age-Related Macular Degeneration (nAMD) | ACTIVE_NOT_RECRUITING | NCT04514653 |
| Local Steroid | Other | Phase PHASE2 | Neovascular Age-Related Macular Degeneration (nAMD) | ACTIVE_NOT_RECRUITING | NCT04514653 |
| ABBV-RGX-314 Dose 3 | Other | Phase PHASE2 | Neovascular Age-Related Macular Degeneration (nAMD) | ACTIVE_NOT_RECRUITING | NCT04514653 |
| ABBV-RGX-314 Dose 2 | Other | Phase PHASE2 | Neovascular Age-Related Macular Degeneration (nAMD) | ACTIVE_NOT_RECRUITING | NCT04514653 |
| ABBV-RGX-314 Dose 1 | Other | Phase PHASE2 | Neovascular Age-Related Macular Degeneration (nAMD) | ACTIVE_NOT_RECRUITING | NCT04514653 |
| Ranibizumab | Other | Phase PHASE2 | Neovascular Age-Related Macular Degeneration (nAMD) | ACTIVE_NOT_RECRUITING | NCT04514653 |
| RGX-111 | Other | Phase PHASE1 | Mucopolysaccharidosis Type I (MPS I) | SUSPENDED | NCT03580083 |
| No Intervention | Other | Preclinical | Duchenne Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06491927 |
| Aflibercept (EYLEA®) | Other | Phase PHASE3 | AMD | RECRUITING | NCT05407636 |
| ABBV-RGX-314 Dose 2 | Other | Phase PHASE3 | AMD | RECRUITING | NCT05407636 |
| ABBV-RGX-314 Dose 1 | Other | Phase PHASE3 | AMD | RECRUITING | NCT05407636 |
| No Intervention | Other | Preclinical | Mucopolysaccharidosis I | ENROLLING_BY_INVITATION | NCT06103487 |
| No Intervention | Other | Preclinical | Mucopolysaccharidosis I | ENROLLING_BY_INVITATION | NCT06103487 |
| No Intervention | Other | Preclinical | Mucopolysaccharidosis I | ENROLLING_BY_INVITATION | NCT06103487 |
| No Intervention | Other | Preclinical | Mucopolysaccharidosis I | ENROLLING_BY_INVITATION | NCT06103487 |
| No Intervention | Other | Preclinical | Mucopolysaccharidosis I | ENROLLING_BY_INVITATION | NCT06103487 |
| Ranibizumab (LUCENTIS®) | Other | Phase PHASE2 | AMD | ACTIVE_NOT_RECRUITING | NCT04704921 |
| ABBV-RGX-314 | Other | Phase PHASE2 | AMD | ACTIVE_NOT_RECRUITING | NCT04704921 |
| No Intervention | Other | Preclinical | Mucopolysaccharidosis I | ENROLLING_BY_INVITATION | NCT06103487 |
| No Intervention | Other | Preclinical | Mucopolysaccharidosis I | ENROLLING_BY_INVITATION | NCT06103487 |
| No Intervention | Other | Preclinical | Mucopolysaccharidosis I | ENROLLING_BY_INVITATION | NCT06103487 |
| No Intervention | Other | Preclinical | Mucopolysaccharidosis I | ENROLLING_BY_INVITATION | NCT06103487 |
| No Intervention | Other | Preclinical | Mucopolysaccharidosis I | ENROLLING_BY_INVITATION | NCT06103487 |
| No Intervention | Other | Preclinical | Mucopolysaccharidosis I | ENROLLING_BY_INVITATION | NCT06103487 |
| Ranibizumab (LUCENTIS®) | Other | Phase PHASE2 | AMD | ACTIVE_NOT_RECRUITING | NCT04704921 |
| ABBV-RGX-314 | Other | Phase PHASE2 | AMD | ACTIVE_NOT_RECRUITING | NCT04704921 |
| No Intervention | Other | Preclinical | Mucopolysaccharidosis I | ENROLLING_BY_INVITATION | NCT06103487 |
| Ranibizumab (LUCENTIS®) | Other | Phase PHASE2 | AMD | ACTIVE_NOT_RECRUITING | NCT04704921 |
| ABBV-RGX-314 | Other | Phase PHASE2 | AMD | ACTIVE_NOT_RECRUITING | NCT04704921 |
| Ranibizumab (LUCENTIS®) | Other | Phase PHASE2 | AMD | ACTIVE_NOT_RECRUITING | NCT04704921 |
| ABBV-RGX-314 | Other | Phase PHASE2 | AMD | ACTIVE_NOT_RECRUITING | NCT04704921 |
| Ranibizumab (LUCENTIS®) | Other | Phase PHASE2 | AMD | ACTIVE_NOT_RECRUITING | NCT04704921 |
| ABBV-RGX-314 | Other | Phase PHASE2 | AMD | ACTIVE_NOT_RECRUITING | NCT04704921 |
| Ranibizumab (LUCENTIS®) | Other | Phase PHASE2 | AMD | ACTIVE_NOT_RECRUITING | NCT04704921 |
| ABBV-RGX-314 | Other | Phase PHASE2 | AMD | ACTIVE_NOT_RECRUITING | NCT04704921 |
| Ranibizumab (LUCENTIS®) | Other | Phase PHASE2 | AMD | ACTIVE_NOT_RECRUITING | NCT04704921 |
| ABBV-RGX-314 | Other | Phase PHASE2 | AMD | ACTIVE_NOT_RECRUITING | NCT04704921 |
| Ranibizumab (LUCENTIS®) | Other | Phase PHASE2 | AMD | ACTIVE_NOT_RECRUITING | NCT04704921 |
| ABBV-RGX-314 | Other | Phase PHASE2 | AMD | ACTIVE_NOT_RECRUITING | NCT04704921 |
| Ranibizumab (LUCENTIS®) | Other | Phase PHASE2 | AMD | ACTIVE_NOT_RECRUITING | NCT04704921 |
| ABBV-RGX-314 | Other | Phase PHASE2 | AMD | ACTIVE_NOT_RECRUITING | NCT04704921 |
| Ranibizumab (LUCENTIS®) | Other | Phase PHASE2 | AMD | ACTIVE_NOT_RECRUITING | NCT04704921 |
| ABBV-RGX-314 | Other | Phase PHASE2 | AMD | ACTIVE_NOT_RECRUITING | NCT04704921 |
| RGX-121-3102 | GENETIC | Phase PHASE3 | MPS II | SUSPENDED | NCT07236606 |
| Aflibercept (2.0 mg) | BIOLOGICAL | Phase PHASE2 | Diabetic Macular Edema | RECRUITING | NCT06942520 |
| RGX-314 Dose 2 | GENETIC | Phase PHASE2 | Diabetic Macular Edema | RECRUITING | NCT06942520 |
| RGX-314 Dose 1 | GENETIC | Phase PHASE2 | Diabetic Macular Edema | RECRUITING | NCT06942520 |
| No Intervention | GENETIC | Preclinical | Duchenne Muscular Dystrophy | ENROLLING_BY_INVITATION | NCT06491927 |
| RGX-202 | GENETIC | Phase PHASE2 | Duchenne Muscular Dystrophy | RECRUITING | NCT05693142 |
| Aflibercept (EYLEA®) | BIOLOGICAL | Phase PHASE3 | AMD | RECRUITING | NCT05407636 |
| Ranibizumab (LUCENTIS®) | BIOLOGICAL | Phase PHASE2 | AMD | RECRUITING | NCT04704921 |
| ABBV-RGX-314 | GENETIC | Phase PHASE2 | AMD | RECRUITING | NCT04704921 |
| Long-term Follow-Up | OTHER | Preclinical | Mucopolysaccharidosis II | ENROLLING_BY_INVITATION | NCT04597385 |
| Observational | OTHER | Preclinical | Mucopolysaccharidosis II | WITHDRAWN | NCT04591834 |
| Aflibercept | BIOLOGICAL | Phase PHASE2 | Diabetic Retinopathy (DR) | ACTIVE_NOT_RECRUITING | NCT04567550 |
| ABBV-RGX-314 Dose 4 | GENETIC | Phase PHASE2 | Diabetic Retinopathy (DR) | ACTIVE_NOT_RECRUITING | NCT04567550 |
| Topical Steroid | DRUG | Phase PHASE2 | Diabetic Retinopathy (DR) | ACTIVE_NOT_RECRUITING | NCT04567550 |
| Local Steroid | DRUG | Phase PHASE2 | Neovascular Age-Related Macular Degeneration (nAMD) | ACTIVE_NOT_RECRUITING | NCT04514653 |
| ABBV-RGX-314 Dose 3 | GENETIC | Phase PHASE2 | Diabetic Retinopathy (DR) | ACTIVE_NOT_RECRUITING | NCT04567550 |
| ABBV-RGX-314 Dose 2 | GENETIC | Phase PHASE3 | AMD | RECRUITING | NCT05407636 |
| ABBV-RGX-314 Dose 1 | GENETIC | Phase PHASE3 | AMD | RECRUITING | NCT05407636 |
| Ranibizumab | BIOLOGICAL | Phase PHASE2 | Neovascular Age-Related Macular Degeneration (nAMD) | ACTIVE_NOT_RECRUITING | NCT04514653 |
| Single intravenous (IV) dose of human Low Density Lipoprotein Receptor (LDLR) Gene Therapy | DRUG | Preclinical | Homozygous Familial Hypercholesterolemia (HoFH) | ACTIVE_NOT_RECRUITING | NCT04080050 |
| RGX-111 | GENETIC | Phase PHASE1 | Mucopolysaccharidosis Type I (MPS I) | SUSPENDED | NCT03580083 |
| RGX-121 | GENETIC | Phase PHASE1 | Mucopolysaccharidosis Type II (MPS II) | COMPLETED | NCT04571970 |
| RGX-314 | GENETIC | Phase PHASE1 | Neovascular Age-related Macular Degeneration | COMPLETED | NCT03066258 |
| AAV directed hLDLR gene therapy | GENETIC | Phase PHASE1 | Homozygous Familial Hypercholesterolemia (HoFH) | TERMINATED | NCT02651675 |
Total products: 94